Reports
Sale
Asia Pacific Anti-Obesity Drugs Market Size, Share, Growth: By Drugs: Semaglutide, Phentermine/Topiramate, Naltrexone/Bupropion, Liraglutide, Gelesis 100, Orlistat, Others; By Drug Class; By Mechanism of Action; By Route of Administration; By Prescription Type; By Distribution Channel; Regional Analysis; Supplier Landscape; 2024-2032
Asia Pacific Anti-Obesity Drugs Market Outlook
The anti-obesity drugs market size was valued at USD 2.5 billion in 2023, with Asia Pacific holding a significant market share. The market is driven by the rising prevalence of obesity. It is expected to grow at a CAGR of 10.70% during the forecast period of 2024-2032, with the values likely to attain USD 6.3 billion by 2032.
Key Takeaways
- It is reported that the obesity prevalence rate in the Asia Pacific region is increasing rapidly. This surge in obesity rates is expected to augment the need for effective weight management solutions including anti-obesity drugs.
- In January 2024, it was reported that Chinese biotechnology company Innovent Biologics Inc. and Eli Lilly and Company’s anti-obesity drug mazdutide achieved positive Phase III results, with data showing a significant reduction in body weight by week 32 and a majority of patients undergoing weight loss of 5% or more. The development of such innovative anti-obesity medications with higher efficacy and fewer side effects is expected to elevate the Asia Pacific anti-obesity drugs market value.
- One of the major market trends is the rising development of biosimilar drugs to provide cost-effective alternatives for weight management. For instance, in April 2024, Hangzhou Jiuyuan Gene Engineering Co., Ltd. revealed that it is seeking marketing approval for Jiyoutai, the first biosimilar drug expected to provide strong competition to Novo Nordisk’s weight-loss and diabetes drugs portfolio in China.
Asia Pacific Anti-Obesity Drugs Market Analysis
Anti-obesity drugs comprise medications that aid in reducing or controlling the weight of an individual such as appetite suppressants, fat absorption inhibitors, and metabolic enhancers. The rising public awareness regarding the risks associated with obesity like cardiovascular diseases, hypertension, and diabetes, is prompting obese patients to seek appropriate treatments including weight loss drugs. Further, increased initiatives from the government to combat obesity are expected to drive the Asia Pacific anti-obesity drugs market growth.
The high prevalence of obesity directly influences the market demand for anti-obesity drugs. It is reported that the obesity prevalence rate in the Asia Pacific region is growing rapidly. In China, over 50% of adults and nearly 20% of school-age children are experiencing overweight conditions . This surge in obesity rates can be attributed to changing dietary habits and increased sedentary lifestyles, which is expected to augment the need for effective weight management solutions, thereby boosting the market share of anti-obesity drugs.
One of the major Asia Pacific anti-obesity drugs market trends is the rising development of biosimilar drugs to provide cost-effective alternatives for weight management. For instance, in April 2024, a Chinese biopharmaceutical company Hangzhou Jiuyuan Gene Engineering Co., Ltd. revealed that it is seeking marketing approval for Jiyoutai (a biosimilar to semaglutide), the first biosimilar drug expected to provide strong competition to Novo Nordisk’s weight-loss and diabetes drugs portfolio in China. The increased access to a wide range of anti-obesity drugs in the region is anticipated to propel the market growth.
The Asia Pacific anti-obesity drugs market share is positively influenced by the ongoing research in obesity treatment solutions which is leading to the introduction of novel anti-obesity drugs. In January 2024, it was reported that Innovent Biologics Inc. (a Chinese biotechnology company) and Eli Lilly and Company’s anti-obesity drug mazdutide (a dual glucagon-like peptide-1 (GLP-1) glucagon receptor agonist) achieved positive Phase III results. In the GLORY-1 trial, the drug met both of its primary endpoints, with data showing a significant reduction in body weight by week 32 and a majority of patients undergoing weight loss of 5% or more. The development of such innovative anti-obesity medications with higher efficacy and fewer side effects is expected to elevate the market value.
Asia Pacific Anti-Obesity Drugs Market Segmentation
The report offers a detailed analysis of the market based on the following segments:
| Market Breakup | Categories |
| Drugs | Semaglutide, Phentermine/Topiramate, Naltrexone/Bupropion, Liraglutide, Gelesis 100, Orlistat, Phentermine, Methamphetamine, Tirzepatide |
| Drug Class | Amphetamine, GLP-1 Receptor Agonist, Lipase Inhibitor |
| Mechanism of Action | Centrally Acting Drugs, Peripherally Acting Drugs |
| Route of Administration | Oral, Subcutaneous |
| Prescription Type | Prescription Drugs, Over the Counter Drugs |
| Distribution Channel | Hospital Pharmacies, Drug Store and Retail Pharmacies, Online Pharmacies |
| Country | China, Japan, ASEAN, Australia, India, Others |
Asia Pacific Anti-Obesity Drugs Market: Competitor Landscape
The key features of the market report include patent analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:
- VIVUS Inc.
- Pfizer, Inc.
- Novo Nordisk
- Bayer AG
- F Hoffmann-La Roche
- Glaxosmithkline
- Arena Pharmaceuticals
- Eisai Co. Ltd
- Takeda Pharmaceutical Company
- Nalpropion Pharmaceuticals Inc.
Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.
Key Highlights of the Report
| REPORT FEATURES | DETAILS |
| Base Year | 2023 |
| Historical Period | 2017-2023 |
| Forecast Period | 2024-2032 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Drugs |
|
| Breakup by Drug Class |
|
| Breakup by Mechanism of Action |
|
| Breakup by Route of Administration |
|
| Breakup by Prescription Type |
|
| Breakup by Distribution Channel |
|
| Breakup by Region |
|
| Market Dynamics |
|
| Supplier Landscape |
|
| Companies Covered |
|
*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.
1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage – Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Asia Pacific Anti-Obesity Drugs Market Overview
3.1 Asia Pacific Anti-Obesity Drugs Market Historical Value (2017-2023)
3.2 Asia Pacific Anti-Obesity Drugs Market Forecast Value (2024-2032)
4 Asia Pacific Anti-Obesity Drugs Market Landscape*
4.1 Asia Pacific Anti-Obesity Drugs Market: Developers Landscape
4.1.1 Analysis by Year of Establishment
4.1.2 Analysis by Company Size
4.1.3 Analysis by Region
4.2 Asia Pacific Anti-Obesity Drugs Market: Product Landscape
4.2.1 Analysis by Product
4.2.2 Analysis by Material
4.2.3 Analysis by Type
5 Asia Pacific Anti-Obesity Drugs Market Dynamics
5.1 Market Drivers and Constraints
5.2 SWOT Analysis
5.2.1 Strengths
5.2.2 Weaknesses
5.2.3 Opportunities
5.2.4 Threats
5.3 Porter’s Five Forces Analysis
5.3.1 Bargaining Power of Suppliers
5.3.2 Bargaining Power of Buyers
5.3.3 Threat of New Entrants
5.3.4 Threat of Substitutes
5.3.5 Degree of Rivalry
5.4 Key Demand Indicators
5.5 Key Price Indicators
5.6 Industry Events, Initiatives, and Trends
5.7 Value Chain Analysis
6 Asia Pacific Anti-Obesity Drugs Market Segmentation (2017-2032)
6.1 Asia Pacific Anti-Obesity Drugs Market (2017-2032) by Drugs
6.1.1 Market Overview
6.1.2 Semaglutide
6.1.3 Phentermine/Topiramate
6.1.4 Naltrexone/Bupropion
6.1.5 Liraglutide
6.1.6 Gelesis 100
6.1.7 Orlistat
6.1.8 Phentermine
6.1.9 Methamphetamine
6.1.10 Tirzepatide
6.2 Asia Pacific Anti-Obesity Drugs Market (2017-2032) by Drug Class
6.2.1 Market Overview
6.2.2 Amphetamine
6.2.3 GLP-1 receptor agonist
6.2.4 Lipase Inhibitor
6.3 Asia Pacific Anti-Obesity Drugs Market (2017-2032) by Mechanism of Action
6.3.1 Market Overview
6.3.2 Centrally Acting Drugs
6.3.3 Peripherally Acting Drugs
6.4 Asia Pacific Anti-Obesity Drugs Market (2017-2032) by Route of Administration
6.4.1 Market Overview
6.4.2 Oral
6.4.3 Subcutaneous
6.5 Asia Pacific Anti-Obesity Drugs Market (2017-2032) by Prescription Type
6.5.1 Market Overview
6.5.2 Prescription Drugs
6.5.3 Over The Counter Drugs
6.6 Asia Pacific Anti-Obesity Drugs Market (2017-2032) by Distribution Channel
6.6.1 Market Overview
6.6.2 Hospital Pharmacies
6.6.3 Drug Store & Retail Pharmacies
6.6.4 Online Pharmacies
6.7 Asia Pacific Anti-Obesity Drugs Market (2017-2032) by Countries
6.7.1 Market Overview
6.7.2 China
6.7.3 Japan
6.7.4 ASEAN
6.7.5 Australia
6.7.6 India
6.7.7 Others
7 China Anti- Obesity Drugs Market (2017-2032)
7.1 China Anti-Obesity Drugs Market (2017-2032) by Drugs
7.1.1 Market Overview
7.1.2 Semaglutide
7.1.3 Phentermine/Topiramate
7.1.4 Naltrexone/Bupropion
7.1.5 Liraglutide
7.1.6 Gelesis 100
7.1.7 Orlistat
7.1.8 Phentermine
7.1.9 Methamphetamine
7.1.10 Tirzepatide
7.2 China Anti-Obesity Drugs Market (2017-2032) by Drug Class
7.2.1 Market Overview
7.2.2 Market Overview
7.2.3 Amphetamine
7.2.4 GLP-1 receptor agonist
7.2.5 Lipase Inhibitor
7.3 China Anti-Obesity Drugs Market (2017-2032) by Mechanism of Action
7.3.1 Market Overview
7.3.2 Centrally Acting Drugs
7.3.3 Peripherally Acting Drugs
7.4 China Anti-Obesity Drugs Market (2017-2032) by Route of Administration
7.4.1 Market Overview
7.4.2 Oral
7.4.3 Subcutaneous
7.5 China Anti-Obesity Drugs Market (2017-2032) by Prescription Type
7.5.1 Market Overview
7.5.2 Prescription Drugs
7.5.3 Over The Counter Drugs
7.6 China Anti-Obesity Drugs Market (2017-2032) by Distribution Channel
7.6.1 Market Overview
7.6.2 Hospital Pharmacies
7.6.3 Drug Store & Retail Pharmacies
7.6.4 Online Pharmacies
8 Japan Anti- Obesity Drugs Market (2017-2032)
8.1 Japan Anti-Obesity Drugs Market (2017-2032) by Drugs
8.1.1 Market Overview
8.1.2 Semaglutide
8.1.3 Phentermine/Topiramate
8.1.4 Naltrexone/Bupropion
8.1.5 Liraglutide
8.1.6 Gelesis 100
8.1.7 Orlistat
8.1.8 Phentermine
8.1.9 Methamphetamine
8.1.10 Tirzepatide
8.2 Japan Anti-Obesity Drugs Market (2017-2032) by Drug Class
8.2.1 Market Overview
8.2.2 Market Overview
8.2.3 Amphetamine
8.2.4 GLP-1 receptor agonist
8.2.5 Lipase Inhibitor
8.3 Japan Anti-Obesity Drugs Market (2017-2032) by Mechanism of Action
8.3.1 Market Overview
8.3.2 Centrally Acting Drugs
8.3.3 Peripherally Acting Drugs
8.4 Japan Anti-Obesity Drugs Market (2017-2032) by Route of Administration
8.4.1 Market Overview
8.4.2 Oral
8.4.3 Subcutaneous
8.5 Japan Anti-Obesity Drugs Market (2017-2032) by Prescription Type
8.5.1 Market Overview
8.5.2 Prescription Drugs
8.5.3 Over The Counter Drugs
8.6 Japan Anti-Obesity Drugs Market (2017-2032) by Distribution Channel
8.6.1 Market Overview
8.6.2 Hospital Pharmacies
8.6.3 Drug Store & Retail Pharmacies
8.6.4 Online Pharmacies
9 ASEAN Anti-Obesity Drugs Market (2017-2032)
9.1 ASEAN Anti-Obesity Drugs Market (2017-2032) by Drugs
9.1.1 Market Overview
9.1.2 Semaglutide
9.1.3 Phentermine/Topiramate
9.1.4 Naltrexone/Bupropion
9.1.5 Liraglutide
9.1.6 Gelesis 100
9.1.7 Orlistat
9.1.8 Phentermine
9.1.9 Methamphetamine
9.1.10 Tirzepatide
9.2 ASEAN Anti-Obesity Drugs Market (2017-2032) by Drug Class
9.2.1 Market Overview
9.2.2 Market Overview
9.2.3 Amphetamine
9.2.4 GLP-1 receptor agonist
9.2.5 Lipase Inhibitor
9.3 ASEAN Anti-Obesity Drugs Market (2017-2032) by Mechanism of Action
9.3.1 Market Overview
9.3.2 Centrally Acting Drugs
9.3.3 Peripherally Acting Drugs
9.4 ASEAN Anti-Obesity Drugs Market (2017-2032) by Route of Administration
9.4.1 Market Overview
9.4.2 Oral
9.4.3 Subcutaneous
9.5 ASEAN Anti-Obesity Drugs Market (2017-2032) by Prescription Type
9.5.1 Market Overview
9.5.2 Prescription Drugs
9.5.3 Over The Counter Drugs
9.6 ASEAN Anti-Obesity Drugs Market (2017-2032) by Distribution Channel
9.6.1 Market Overview
9.6.2 Hospital Pharmacies
9.6.3 Drug Store & Retail Pharmacies
9.6.4 Online Pharmacies
10 Australia Anti-Obesity Drugs Market (2017-2032)
10.1 Australia Anti-Obesity Drugs Market (2017-2032) by Drugs
10.1.1 Market Overview
10.1.2 Semaglutide
10.1.3 Phentermine/Topiramate
10.1.4 Naltrexone/Bupropion
10.1.5 Liraglutide
10.1.6 Gelesis 100
10.1.7 Orlistat
10.1.8 Phentermine
10.1.9 Methamphetamine
10.1.10 Tirzepatide
10.2 Australia Anti-Obesity Drugs Market (2017-2032) by Drug Class
10.2.1 Market Overview
10.2.2 Market Overview
10.2.3 Amphetamine
10.2.4 GLP-1 receptor agonist
10.2.5 Lipase Inhibitor
10.3 Australia Anti-Obesity Drugs Market (2017-2032) by Mechanism of Action
10.3.1 Market Overview
10.3.2 Centrally Acting Drugs
10.3.3 Peripherally Acting Drugs
10.4 Australia Anti-Obesity Drugs Market (2017-2032) by Route of Administration
10.4.1 Market Overview
10.4.2 Oral
10.4.3 Subcutaneous
10.5 Australia Anti-Obesity Drugs Market (2017-2032) by Prescription Type
10.5.1 Market Overview
10.5.2 Prescription Drugs
10.5.3 Over The Counter Drugs
10.6 Australia Anti-Obesity Drugs Market (2017-2032) by Distribution Channel
10.6.1 Market Overview
10.6.2 Hospital Pharmacies
10.6.3 Drug Store & Retail Pharmacies
10.6.4 Online Pharmacies
11 India Anti-Obesity Drugs Market (2017-2032)
11.1 India Anti-Obesity Drugs Market (2017-2032) by Drugs
11.1.1 Market Overview
11.1.2 Semaglutide
11.1.3 Phentermine/Topiramate
11.1.4 Naltrexone/Bupropion
11.1.5 Liraglutide
11.1.6 Gelesis 100
11.1.7 Orlistat
11.1.8 Phentermine
11.1.9 Methamphetamine
11.1.10 Tirzepatide
11.2 India Anti-Obesity Drugs Market (2017-2032) by Drug Class
11.2.1 Market Overview
11.2.2 Market Overview
11.2.3 Amphetamine
11.2.4 GLP-1 receptor agonist
11.2.5 Lipase Inhibitor
11.3 India Anti-Obesity Drugs Market (2017-2032) by Mechanism of Action
11.3.1 Market Overview
11.3.2 Centrally Acting Drugs
11.3.3 Peripherally Acting Drugs
11.4 India Anti-Obesity Drugs Market (2017-2032) by Route of Administration
11.4.1 Market Overview
11.4.2 Oral
11.4.3 Subcutaneous
11.5 India Anti-Obesity Drugs Market (2017-2032) by Prescription Type
11.5.1 Market Overview
11.5.2 Prescription Drugs
11.5.3 Over The Counter Drugs
11.6 India Anti-Obesity Drugs Market (2017-2032) by Distribution Channel
11.6.1 Market Overview
11.6.2 Hospital Pharmacies
11.6.3 Drug Store & Retail Pharmacies
11.6.4 Online Pharmacies
12 Regulatory Framework
13 Patent Analysis
13.1 Analysis by Type of Patent
13.2 Analysis by Publication year
13.3 Analysis by Issuing Authority
13.4 Analysis by Patent Age
13.5 Analysis by CPC Analysis
13.6 Analysis by Patent Valuation
13.7 Analysis by Key Players
14 Funding and Investment Analysis
14.1 Analysis by Funding Instances
14.2 Analysis by Type of Funding
14.3 Analysis by Funding Amount
14.4 Analysis by Leading Players
14.5 Analysis by Leading Investors
14.6 Analysis by Geography
15 Partnership and Collaborations Analysis
15.1 Analysis by Partnership Instances
15.2 Analysis by Type of Partnership
15.3 Analysis by Leading Players
15.4 Analysis by Geography
16 Supplier Landscape
16.1 Market Share by Top 5 Companies
16.2 VIVUS Inc
16.2.1 Financial Analysis
16.2.2 Product Portfolio
16.2.3 Demographic Reach and Achievements
16.2.4 Mergers and Acquisitions
16.2.5 Certifications
16.3 Pfizer, Inc.
16.3.1 Financial Analysis
16.3.2 Product Portfolio
16.3.3 Demographic Reach and Achievements
16.3.4 Mergers and Acquisitions
16.3.5 Certifications
16.4 Novo Nordisk
16.4.1 Financial Analysis
16.4.2 Product Portfolio
16.4.3 Demographic Reach and Achievements
16.4.4 Mergers and Acquisitions
16.4.5 Certifications
16.5 Bayer AG
16.5.1 Financial Analysis
16.5.2 Product Portfolio
16.5.3 Demographic Reach and Achievements
16.5.4 Mergers and Acquisitions
16.5.5 Certifications
16.6 F Hoffmann-La Roche
16.6.1 Financial Analysis
16.6.2 Product Portfolio
16.6.3 Demographic Reach and Achievements
16.6.4 Mergers and Acquisitions
16.6.5 Certifications
16.7 Glaxosmithkline
16.7.1 Financial Analysis
16.7.2 Product Portfolio
16.7.3 Demographic Reach and Achievements
16.7.4 Mergers and Acquisitions
16.7.5 Certifications
16.8 Arena Pharmaceuticals
16.8.1 Financial Analysis
16.8.2 Product Portfolio
16.8.3 Demographic Reach and Achievements
16.8.4 Mergers and Acquisitions
16.8.5 Certifications
16.9 Eisai Co. Ltd
16.9.1 Financial Analysis
16.9.2 Product Portfolio
16.9.3 Demographic Reach and Achievements
16.9.4 Mergers and Acquisitions
16.9.5 Certifications
16.10 Takeda Pharmaceutical Company
16.10.1 Financial Analysis
16.10.2 Product Portfolio
16.10.3 Demographic Reach and Achievements
16.10.4 Mergers and Acquisitions
16.10.5 Certifications
16.11 Nalpropion Pharmaceuticals Inc
16.11.1 Financial Analysis
16.11.2 Product Portfolio
16.11.3 Demographic Reach and Achievements
16.11.4 Mergers and Acquisitions
16.11.5 Certifications
17 Asia Pacific Anti-Obesity Drugs Market – Distribution Model (Additional Insight)
17.1 Overview
17.2 Potential Distributors
17.3 Key Parameters for Distribution Partner Assessment
18 Key Opinion Leaders (KOL) Insights (Additional Insight)
19 Company Competitiveness Analysis (Additional Insight)
19.1 Very Small Companies
19.2 Small Companies
19.3 Mid-Sized Companies
19.4 Large Companies
19.5 Very Large Companies
20 Payment Methods (Additional Insight)
20.1 Government Funded
20.2 Private Insurance
20.3 Out-of-Pocket
*Additional insights provided are customisable as per client requirements.
* The coverage of the Market Landscape section depends on the data availability and may cover a minimum of 80% of the total market. The EMR team strives to make this section as comprehensive as possible.
Key Questions Answered in the Report
The Asia Pacific anti-obesity drugs market is expected to be driven by the rising demand for the global market, which is anticipated to grow at a CAGR of 10.70% during the forecast period of 2024-2032 and is likely to reach a market value of USD 6.3 billion by 2032.
The rising obesity rates and increased initiatives from the government are fuelling the demand for the market.
One of the significant trends is the rising development of biosimilar drugs to provide cost-effective alternatives for weight management. For instance, in April 2024, Hangzhou Jiuyuan Gene Engineering Co., Ltd. revealed that it is seeking marketing approval for Jiyoutai, the first biosimilar drug expected to provide competition to Novo Nordisk’s weight-loss and diabetes drugs portfolio in China.
Based on the drugs, the market is segmented into semaglutide, phentermine/topiramate, naltrexone/bupropion, liraglutide, gelesis 100, orlistat, phentermine, methamphetamine, and tirzepatide.
Drug classes available in the market include amphetamine, GLP-1 receptor agonist, and lipase inhibitors.
By mechanism of action, the market is divided into centrally acting drugs and peripherally acting drugs.
The market breakup by route of administration includes oral and subcutaneous.
The market breakup by prescription type includes prescription drugs and over the counter drugs.
Distribution channels of the market are hospital pharmacies, drug stores, retail pharmacies, and online pharmacies.
The market segmentation by countries includes China, Japan, India, ASEAN, and Australia, among others.
The key players in the market are VIVUS Inc., Pfizer Inc., Novo Nordisk, Bayer AG, F. Hoffmann-La Roche, Glaxosmithkline, Arena Pharmaceuticals, Eisai Co. Ltd, Takeda Pharmaceutical Company, and Nalpropion Pharmaceuticals Inc.
Purchase Options 10% off
Call us
Purchase Full Report
Mini Report
$ 2639
$2399
-
Selected Sections, One User
-
Printing Not Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Single User License
$ 4399
$3999
-
All Sections, One User
-
One Print Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Five User License
$ 5829
$5299
-
All Sections, Five Users
-
Five Prints Allowed
-
Email Delivery in PDF
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Corporate License
$ 6929
$6299
-
All Sections, Unlimited Users
-
Unlimited Prints Allowed
-
Email Delivery in PDF + Excel
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Any Question? Speak With An Analyst
View A Sample
Did You Miss Anything, Ask Now
Why Expert Market Research?
Right People
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
Right Methodology
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
Right Price
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
Right Support
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.
NEWSLETTER